Defining influenza-specific B cells in vaccine responders, non-responders and influenza breakthrough infections

This study utilizes single-cell transcriptomics to reveal that elevated frequencies of atypical B cells, characterized by specific markers and gene expression profiles, are a key determinant of both influenza vaccine non-responsiveness and severe infection outcomes.

The Gist

Imagine your immune system is a highly trained security team guarding a castle (your body). The "guards" are your B cells, and their job is to recognize and neutralize invaders like the flu virus. Every year, the castle owners give the guards a "wanted poster" (the flu vaccine) showing what the current flu criminals look like, hoping the guards will learn to spot them and stop them before they break in.

However, sometimes the guards don't learn the lesson. They see the poster but don't actually get better at catching the criminal. This is what scientists call a "non-responder."

This paper is like a detective story where researchers went deep inside the security team's training logs to figure out why some guards fail to learn, while others become elite snipers. They used a super-powerful microscope (single-cell sequencing) to read the "diaries" of individual B cells.

Here is the breakdown of their findings in simple terms:

1. The Big Problem: Half the Guards Don't Learn

The researchers looked at data from 2015 to 2022 and found a shocking statistic: 50% to 60% of people who get the flu shot do not develop a strong new defense against the specific flu strains in the vaccine. They don't produce enough new "wanted posters" (antibodies) to be considered protected.

2. The "Burned-Out" Guards (Atypical B Cells)

The team discovered a specific type of guard called "Atypical B cells."

• The Metaphor: Imagine a guard who has seen too many movies, fought too many battles, or is just tired. They are still on duty, but they are "burned out." They are present, but they aren't very good at learning new tricks or making new weapons.
• The Finding: In people who failed to respond to the vaccine, the researchers found a huge number of these "burned-out" guards before they even got the shot. It's like trying to teach a new dance move to a room full of exhausted dancers; they just can't pick it up.
• The Contrast: People who did respond well to the vaccine had a diverse mix of fresh, energetic guards ready to learn.

3. The "ID Badge" Clues

The researchers looked at the "ID badges" (proteins) on the surface of these cells to see what was different.

• The Good Guards (Responders): Had badges that said "I am ready to work!" (High levels of HLA-DR and CD74). These badges help the guards talk to other parts of the immune system and get activated.
• The Burned-Out Guards (Non-Responders & Sick Patients): Had missing or faded badges. Their "communication chips" were turned down. This suggests they are stuck in a state where they can't easily get the signal to start fighting.

4. The "Breakthrough" Infections

The study also looked at people who got vaccinated but still got the flu (breakthrough infections).

• The Discovery: Even after getting the shot, if these people got sick, their immune systems were flooded with those same "burned-out" guards.
• The Twist: The researchers found that these "burned-out" guards actually change their behavior depending on whether they are reacting to the vaccine or the actual virus. It's like the guards have two different "modes" of exhaustion: one for training (vaccine) and one for the real battle (infection).

5. The Hospitalized Patients (The Worst Case Scenario)

Finally, they looked at people who were so sick with the flu they had to go to the hospital.

• The Shock: These patients had the highest number of "burned-out" guards.
• The Implication: When the flu is severe, the immune system seems to get overwhelmed and switches into a "shutdown" mode. The guards stop making new weapons and stop talking to each other. This explains why some people get very sick—their security team is present but paralyzed.

The Bottom Line

This paper tells us that the reason the flu shot doesn't work for everyone isn't just bad luck. It's because some people's immune systems are already filled with "tired" or "burned-out" guards (Atypical B cells) that can't learn new tricks.

Why does this matter?
If we know that "burned-out" guards are the problem, scientists can try to design new vaccines or adjuvants (vaccine boosters) that specifically wake these guards up, or help them get rid of the tired ones. Instead of just showing the guards a new poster, we might need to give them a cup of coffee first!

In short: The flu shot fails for many because their immune "security team" is already exhausted. To fix this, we need to figure out how to refresh the team so they can actually learn the new moves.

Technical Summary

1. Problem Statement

Seasonal influenza vaccination programs are a critical public health intervention, yet they exhibit significant variability in efficacy. Data from cohorts between 2015 and 2022 indicate that 50–60% of individuals fail to seroconvert (defined as a ≥4-fold increase in Hemagglutination Inhibition [HAI] titers) following inactivated influenza vaccine (IIV) administration. The cellular and molecular mechanisms driving this "non-responsiveness" remain poorly understood. Furthermore, there is a lack of understanding regarding the B cell immune landscape in individuals who experience breakthrough infections despite vaccination, and those who suffer severe, hospitalized influenza. The study aims to define the determinants of optimal B cell responses and identify why humoral immunity fails in specific subpopulations.

2. Methodology

The study employed a multi-cohort approach combining single-cell RNA sequencing (scRNA-seq), VDJ sequencing, and flow cytometry to analyze B cell immunity across three distinct groups:

• Healthy Vaccinees: 162 adults vaccinated with IIV (2015–2022). Participants were stratified into Responders (R) and Non-Responders (NR) based on HAI seroconversion and baseline antibody titers (Low/High).
• Breakthrough Infection Cohort: Four participants from the RETAIN cohort (Hong Kong) with documented breakthrough influenza infections (A/H1N1 or A/H3N2) post-vaccination.
• Hospitalized Patients: 16 patients hospitalized with acute influenza (IAV or IBV) and 8 healthy controls (matched for age/sex).

Key Technical Approaches:

• Antigen-Specific Sorting: Recombinant Hemagglutinin (rHA) probes (biotinylated, tetramerized) targeting all four vaccine components (A/H1N1, A/H3N2, B/Victoria, B/Yamagata) were used to sort influenza-specific B cells from PBMCs.
• Multi-omics Sequencing:
  • scRNA-seq (10x Genomics): Performed on rHA+ B cells and bulk B cells.
  • CITE-seq: Used to simultaneously measure surface protein expression (e.g., CD11c, CD21, CD27, CXCR3) alongside transcriptomics.
  • VDJ Sequencing: Analyzed B cell receptor (BCR) clonality and V(D)J gene usage.
• Bioinformatics: Weighted Nearest Neighbor (WNN) UMAP integration of gene expression and protein data. Differential Gene Expression (DGE) analysis using pseudo-bulk approaches (edgeR).
• Flow Cytometry: Validated transcriptomic findings by profiling CD11c, FcRL-5, CD74, HLA-DR, CD83, and CXCR3 on rHA-specific and bulk B cells.

3. Key Contributions

• Definition of Non-Responder Phenotype: Identified that atypical B cells (atB cells) are the dominant subset in vaccine non-responders at baseline, contrasting with the diverse B cell phenotypes seen in responders.
• Novel Discovery in Acute Infection: First to report that hospitalized patients with severe acute influenza exhibit significantly elevated proportions of atypical B cells (CD21-CD27-), a phenomenon previously associated mainly with chronic infections (e.g., HIV, Malaria).
• Molecular Signatures of Failure: Mapped specific gene expression signatures (e.g., HLA-DR, CD74, CD83, CXCR3) that distinguish responders from non-responders and healthy controls from severe cases.
• Breakthrough Infection Dynamics: Described distinct atypical B cell clusters (IRF8+ vs. IRF9+) that emerge post-vaccination versus post-infection, suggesting different activation pathways.

4. Key Results

A. Vaccine Responders vs. Non-Responders

• Seroconversion Rates: Approximately 61% of participants did not seroconvert. A significant portion of non-responders had high baseline HAI titers (High Non-Responders), suggesting pre-existing immunity may blunt the response to new antigens.
• Atypical B Cell Dominance: Non-responders displayed significantly higher frequencies of atypical B cells (characterized by CD11c+, FcRL-5+, CD21-, CD27-) specific to A/H1N1 and A/H3N2 at baseline (Day 0) compared to responders.
• Transcriptomic Signatures:
  • Responders: Upregulated genes included IFITM3, IGHE, TCL1A, HLA-DQB2, and CNTNAP2.
  • Non-Responders: Upregulated genes included CST7, AIRE, ZBTB32, and NR4A2.
  • Common Markers: Non-responders showed elevated expression of atypical markers (CD11c, FcRL-5) and specific chemokine receptors (CXCR3).
• BCR Repertoire: Responders to A/H3N2 showed increased usage of the heavy chain segment IGHV3-23. Non-responders showed increased usage of light chain segments IGKV3-20 and IGLV3-1.

B. Breakthrough Infections

• Distinct Clusters: scRNA-seq of breakthrough cases revealed two unique atypical B cell clusters:
  • Cluster 2 (atB IRF8+): Characterized by CD83 and NR4 family expression.
  • Cluster 5 (atB IRF9+): Characterized by FCRL3/5, IRF2, and interferon-induced genes (IFI30, MX1, OAS1).
• Dynamic Shift: In a specific case study (Participant Q115), rHA-specific B cells shifted from the IRF8+ cluster (post-vaccination) to the IRF9+ cluster (post-infection), indicating a distinct transcriptional program triggered by active viral infection.

C. Hospitalized Patients (Severe Influenza)

• Atypical B Cell Expansion: Hospitalized patients had significantly higher proportions of CD21-CD27- atypical B cells (8.0% vs. 3.7% in healthy controls).
• Reduced Activation Markers: Compared to healthy controls, hospitalized patients showed significantly reduced expression of:
  • CD74 (MHC II chaperone): Suggesting reduced proliferation and antigen presentation capacity.
  • HLA-DR (MHC II): Implicating a failure in B cell-T cell interaction.
  • CD83 (Activation marker): Associated with reduced antibody production.
• Co-expression Patterns: A higher proportion of B cells in hospitalized patients were quadruple-negative for CD74, CD83, CXCR3, HLA-DR, indicating a state of immune exhaustion or dysregulation.

5. Significance

• Mechanistic Insight: The study establishes a direct link between the pre-existing frequency of atypical B cells and the failure to mount a protective antibody response to influenza vaccination.
• Biomarker Discovery: Identifies CD74, HLA-DR, CD83, and CXCR3 as critical markers for assessing B cell functionality and predicting severe outcomes in influenza infection.
• Clinical Implications:
  • The findings suggest that individuals with high baseline atypical B cell frequencies may require alternative vaccination strategies (e.g., adjuvants, higher doses, or different platforms) to overcome immune refractoriness.
  • The discovery of atypical B cell expansion in acute severe influenza challenges the notion that these cells are exclusive to chronic conditions, suggesting they may play a role in immunopathology or immune exhaustion during severe acute viral infections.
• Future Directions: These insights provide a roadmap for designing next-generation vaccines that specifically target the generation of protective memory B cells while mitigating the expansion of non-functional atypical B cells.